The proposed mergers between Aetna and Humana, Anthem and Cigna, and Centene and Health Net and the impact of such consolidations are discussed. Health economist Austin Frakt made it clear that all health economists feel the same way about consolidation in the healthcare market: it’s not good for consumers.
“There’s unanimity on this issue that when you have consolidation among health insurers or providers, you generally don’t get good results for consumers,” Frakt said. He added that generally the result is higher prices. Sometimes there will be higher quality of care, but not always, and if higher quality is a result, people should be asking, “Is the higher quality worth the higher price?”
Leah Binder added that it’s not just consolidations of payers because there are also a lot of mergers happening at the provider level too. Studies have found that when there is consolidation of hospital system, quality usually goes down and cost goes up even though the mergers always promise the opposite.
Frakt admitted that while it is true that consolidation can lead to greater efficiencies and reduced costs, often the merger doesn’t reduce costs for those who are paying. It is possible that insurance consolidation will offset provider consolidation, but the savings do not normally translate to the premiums consumers are paying, he said.
When the insurers and the providers get so big, we need to be careful that the consumer does not get stuck in the middle, Matt Salo said.
“And all this, it’s all about checks and balances and with insurance companies and hospitals and other providers and payers and the consumer, when you tilt the market with consolidation, you run a real risk of upsetting that set of checks and balances,” Salo said. “I think you need to be real careful.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More